Literature DB >> 9927576

Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion.

J S Kahn1, M J Schnell, L Buonocore, J K Rose.   

Abstract

The genes encoding the respiratory syncytial virus (RSV) attachment (G) and fusion (F) envelope glycoproteins were expressed separately as additional genes in recombinant vesicular stomatitis viruses (VSV). Cells infected with the VSV-RSV F recombinant formed large syncytia illustrating the fusion activity of F in absence of other RSV proteins. Both F and G glycoproteins were expressed at the cell surface and incorporated into virions. Incorporation of these proteins did not require cytoplasmic tail sequences of VSV G. Using a compound, ammonium chloride, that raises the endosomal pH, we showed that presence of the RSV F glycoprotein in the envelope of recombinant VSV allowed for infectivity through a low-pH-independent pathway. Recombinant VSV expressing RSV glycoproteins could be useful as an RSV vaccine. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9927576     DOI: 10.1006/viro.1998.9535

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  65 in total

1.  The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil.

Authors:  J M Matthews; T F Young; S P Tucker; J P Mackay
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles.

Authors:  Ki Jeong Lee; Mar Perez; Daniel D Pinschewer; Juan Carlos de la Torre
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response.

Authors:  E B Flanagan; L A Ball; G W Wertz
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Recombinant rinderpest vaccines expressing membrane-anchored proteins as genetic markers: evidence of exclusion of marker protein from the virus envelope.

Authors:  E P Walsh; M D Baron; L F Rennie; P Monaghan; J Anderson; T Barrett
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Role of plasma membrane lipid microdomains in respiratory syncytial virus filament formation.

Authors:  Lewis H McCurdy; Barney S Graham
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 6.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Authors:  David K Clarke; R Michael Hendry; Vidisha Singh; John K Rose; Stephen J Seligman; Bettina Klug; Sonali Kochhar; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2016-07-06       Impact factor: 3.641

7.  The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion.

Authors:  Imogen M Bermingham; Keith J Chappell; Daniel Watterson; Paul R Young
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

8.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 9.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Seroepidemiology of human metapneumovirus (hMPV) on the basis of a novel enzyme-linked immunosorbent assay utilizing hMPV fusion protein expressed in recombinant vesicular stomatitis virus.

Authors:  Jessica Leung; Frank Esper; Carla Weibel; Jeffrey S Kahn
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.